Skip to main content
Clinical Trials/CTRI/2023/07/055689
CTRI/2023/07/055689
Not Yet Recruiting
Phase 4

A Clinical Study to Evaluate the Safety and Efficacy of Panchakarma Essential (Nirgundi-based formulation) in reducing symptoms of Knee Osteoarthritis. - NI

Mprex Healthcare Pvt. Ltd.0 sites0 target enrollmentTBD

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Not specified
Sponsor
Mprex Healthcare Pvt. Ltd.
Status
Not Yet Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\. Male and female subjects 30\-60 years of age (both inclusive)
  • 2\. The patient diagnosed with an OA of the knee for greater than 3 months
  • 3\. VAS (visual analog scale) score during the most painful knee movement between 40\-70 mm.
  • 4\. Subjects with or without consuming analgesics and anti\-inflammatory medicines.
  • 5\. Willing to refrain from taking ibuprofen, aspirin, other NSAIDs, or any other pain reliever (OTC or prescription) during the entire trial.
  • 6\. Ambulatory subject able to provide verbal and written consent and ready to comply with all study procedures.

Exclusion Criteria

  • 1\. Female subjects, who are pregnant, breastfeeding, or planning to become pregnant.
  • 2\. Recent injury in the area affected by OA of the knee (past 4 months)
  • 4\. History of underlying inflammatory arthropathy or severe OA (VAS score greater than 70\)
  • 5\. Have taken any intra\-articular treatment/injections with a corticosteroid or hyaluronic acid within 6 months preceding the treatment period.
  • 6\. History of psychiatric disorder that may impair the ability of subjects to provide written informed consent
  • 7\. Participation in any osteoarthritis related trials involving investigational products within 30 days prior to the screening Visit.

Outcomes

Primary Outcomes

Not specified

Similar Trials